Syndicom SpineConnect Web Platform Chosen for Applied Spine's Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilizat...( Better collaboration and surgeon-to...),Health

Better collaboration and surgeon-to-surgeon communication leads to more

accurate clinical trial results in Stabilimax NZ study

DURANGO, Colo. and NEW HAVEN, Conn., Sept. 18 /PRNewswire/ -- Syndicom, the premier developer of collaborative innovation networks, today announced that the company is providing its SpineConnect platform to facilitate a clinical study for Applied Spine's Stabilimax NZ(R) Dynamic Spine Stabilization System. Stabilimax NZ is a medical device designed to provide stabilization of the lumbar spine in patients receiving decompression surgery for the treatment of spinal stenosis.

"Today's clinical trial landscape is littered with trials that fail to meet their planned timelines and patient accrual goals," said Thomas E. Wood, CEO of Applied Spine. "What has really surprised us is how Syndicom's technology has evolved like an ecosystem to support our changing needs during this clinical trial. I view it as a piece of soft clay that we can mold to fit our needs. The platform is flexible enough so that it can meet the expanding needs of our company."

Prior to partnering with Syndicom, Applied Spine faced a challenge familiar to medical device companies conducting clinical trials: Because the participating investigators are spread out across the United States in 20 sites, efficient communication between the parties is problematic. Typically Principal Investigators (PIs) collected the patient data submitted by the surgeon investigators and met one to two times a year to go through the patient cases post-operatively -- a highly inefficient process. Now for the first time, investigators from around the world can review all the trial cases in an organized, easily accessible, and thoroughly documented way to identify problems earlier and take corrective action sooner, thus reducing overall trial costs.

"Applied Spine and other leading medical device companies are under tremendous pressure to meet regulatory requirem
'/>"/>